TENX News and Press, Tenax Therapeutics Inc. From 01/31/22

MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today ...

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible Extensions MORRISVILLE, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty ph...

Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to Oral Transition Substudy for TNX-103 (oral levosimendan) Plans to Initiate Phase 3 Study of TNX-201 (oral imatinib mesylate) in Pulmonary Arteria...

Tenax Therapeutics (NASDAQ:TENX): Q3 GAAP EPS of -$0.15 misses by $0.02. Cash and cash equivalents of $8.34M Press Release For further details see: Tenax Therapeutics EPS misses by $0.02

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the third quarter of 2021 and...

Unique, Delayed-Release Formulation of Imatinib Designed to Avoid Gastric Intolerance On Track to Initiate a Single Phase 3 in PAH in 2Q 2022 Recently Updated Company Website Highlights Imatinib Clinical Program Tenax Therapeutics, Inc. (Nasdaq: TENX), a ...

Xenon Pharmaceuticals XENE +90% on positive XEN1101 data in mid-stage focal epilepsy study Elmira Savings Bank ESBK +66% Community Bank System to buy Elmira Savings Bank in $82.8M all cash deal OpGen OPGN +30% after announcing preliminary Q3 revenue ahead of expe...

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview at the virtual Benziga ...

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview and hold virtual invest...

Tenax Therapeutics (NASDAQ:TENX): Q2 GAAP EPS of -$0.10. Revenue of $2.2M Press Release For further details see: Tenax Therapeutics reports Q2 results